U.S. markets close in 1 hour 27 minutes

Trevena, Inc. (TRVN)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
1.0800+0.0100 (+0.93%)
As of 2:33PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close1.0700
Bid1.0800 x 2200
Ask1.0900 x 2900
Day's Range1.0700 - 1.1000
52 Week Range1.0600 - 3.1000
Avg. Volume1,167,440
Market Cap177.67M
Beta (5Y Monthly)2.41
PE Ratio (TTM)N/A
EPS (TTM)-0.2630
Earnings DateNov 01, 2021 - Nov 05, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est5.33
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for TRVN

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Trevena, Inc.
    Daily – Vickers Top Buyers & Sellers for 06/29/2021The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Fair Value
    Economic Moat
    4 months agoArgus Research
View more
  • Zacks

    Earnings Preview: Trevena (TRVN) Q3 Earnings Expected to Decline

    Trevena (TRVN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • GlobeNewswire

    Trevena Announces Two OLINVYK® Presentations at ANESTHESIOLOGY® 2021

    Posters highlight safety and tolerability data in two complex patient populations at higher risk for adverse eventsCHESTERBROOK, Pa., Oct. 13, 2021 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced two presentations at ANESTHESIOLOGY® 2021, the national conference for the American Society of Anesthesiologists (ASA). Both posters

  • TipRanks

    Is Trevena Stock a Buy Right Now? This Is What You Need to Know

    On Thursday, tiny King of Prussia, Pennsylvania-based biotech Trevena (TRVN) released the data from an Imperial College London trial involving 30 patients enrolled in the proof-of-concept study of its TRV027 treatment for hospitalized COVID-19 patients. "The results showed that TRV027 was well-tolerated and provided initial evidence of its potential to improve biomarker and clinical endpoints associated with COVID-19 disease severity and progression," reported Trevena, and patients treated with